Cascadian Therapeutics Stock Price, News & Analysis (NASDAQ:CASC)

$3.65 -0.04 (-1.08 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$3.65
Today's Range$3.63 - $3.76
52-Week Range$3.18 - $5.51
Volume1.23 million shs
Average Volume425,099 shs
Market Capitalization$184.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34

About Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics logoCascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive CASC News and Ratings via Email

Sign-up to receive the latest news and ratings for CASC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CASC
CUSIP68232410
Phone206-801-2100

Debt

Debt-to-Equity RatioN/A
Current Ratio11.86%
Quick Ratio11.86%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book1.11

Profitability

Trailing EPS($1.35)
Net Income$-57,700,000.00
Net MarginsN/A
Return on Equity-42.97%
Return on Assets-40.44%

Miscellaneous

Employees57
Outstanding Shares50,560,000

Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions

What is Cascadian Therapeutics' stock symbol?

Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."

How were Cascadian Therapeutics' earnings last quarter?

Cascadian Therapeutics Inc (NASDAQ:CASC) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same quarter last year, the firm posted ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History.

Where is Cascadian Therapeutics' stock going? Where will Cascadian Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Cascadian Therapeutics' shares. Their predictions range from $4.00 to $10.00. On average, they anticipate Cascadian Therapeutics' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Cascadian Therapeutics.

What are Wall Street analysts saying about Cascadian Therapeutics stock?

Here are some recent quotes from research analysts about Cascadian Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (11/14/2017)
  • 2. Cantor Fitzgerald analysts commented, "Pooled analysis from Phase Ib trial in HER2+ metastatic breast cancer patients with or without brain metastases demonstrated similarity in PFS between two groups (264P), which is a secondary endpoint in the HER2CLIMB trial." (9/11/2017)
  • 3. Cowen Inc analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)

Who are some of Cascadian Therapeutics' key competitors?

Who are Cascadian Therapeutics' key executives?

Cascadian Therapeutics' management team includes the folowing people:

  • Christopher S. Henney Ph.D., Chairman of the Board
  • Scott D. Myers, President, Chief Executive Officer, Director
  • Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary
  • Gary W. Christianson, Chief Operating Officer
  • Scott Peterson Ph.D., Chief Scientific Officer
  • Robert W. Azelby, Director
  • Gwendolyn A. Fyfe M.D., Independent Director
  • Steven P. James, Independent Director
  • Ted W. Love M.D., Independent Director
  • Daniel Keith Spiegelman, Independent Director

Who owns Cascadian Therapeutics stock?

Cascadian Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (1.01%), P.A.W. Capital Corp (0.47%), OxFORD Asset Management LLP (0.27%) and JPMorgan Chase & Co. (0.18%). Company insiders that own Cascadian Therapeutics stock include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Institutional Ownership Trends for Cascadian Therapeutics.

Who sold Cascadian Therapeutics stock? Who is selling Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP. View Insider Buying and Selling for Cascadian Therapeutics.

Who bought Cascadian Therapeutics stock? Who is buying Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, P.A.W. Capital Corp and JPMorgan Chase & Co.. Company insiders that have bought Cascadian Therapeutics stock in the last two years include Christopher S Henney, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Insider Buying and Selling for Cascadian Therapeutics.

How do I buy Cascadian Therapeutics stock?

Shares of Cascadian Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cascadian Therapeutics' stock price today?

One share of Cascadian Therapeutics stock can currently be purchased for approximately $3.65.

How big of a company is Cascadian Therapeutics?

Cascadian Therapeutics has a market capitalization of $184.54 million. The biopharmaceutical company earns $-57,700,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Cascadian Therapeutics employs 57 workers across the globe.

How can I contact Cascadian Therapeutics?

Cascadian Therapeutics' mailing address is 2601 FOURTH AVENUE SUITE 500, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-801-2100 or via email at [email protected]


MarketBeat Community Rating for Cascadian Therapeutics (CASC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cascadian Therapeutics (NASDAQ:CASC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.402.402.402.75
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$6.00$5.67
Price Target Upside: 67.13% upside67.13% upside67.13% upside44.93% upside

Cascadian Therapeutics (NASDAQ:CASC) Consensus Price Target History

Price Target History for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ:CASC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Cantor FitzgeraldReiterated RatingHold$4.00MediumView Rating Details
9/6/2017BarclaysInitiated CoverageUnderweight$4.00HighView Rating Details
8/9/2017CowenReiterated RatingBuyHighView Rating Details
4/21/2017BTIG ResearchInitiated CoverageBuyHighView Rating Details
3/11/2017Jefferies GroupReiterated RatingBuy$15.00 -> $10.00N/AView Rating Details
3/15/2016Raymond James FinancialLower Price Target$5.00 -> $3.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Cascadian Therapeutics (NASDAQ:CASC) Earnings History and Estimates Chart

Earnings by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ CASC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.29)($0.28)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.36)($0.30)ViewListenView Earnings Details
5/9/2017Q1 2017($0.39)($0.30)ViewListenView Earnings Details
3/9/2017Q4 2016($0.52)($0.47)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.08)($0.09)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.10)($0.14)ViewN/AView Earnings Details
3/14/2016Q4($0.08)($0.10)ViewN/AView Earnings Details
11/5/2015Q315($0.10)($0.05)ViewListenView Earnings Details
8/6/2015Q215($0.08)($0.11)ViewN/AView Earnings Details
5/11/2015Q115($0.08)($0.08)ViewListenView Earnings Details
3/10/2015Q414($0.09)($0.30)ViewListenView Earnings Details
11/6/2014Q314($0.11)($0.09)ViewN/AView Earnings Details
8/11/2014Q214($0.13)($0.09)ViewN/AView Earnings Details
5/1/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/13/2014Q413($0.10)($0.09)ViewN/AView Earnings Details
11/12/2013Q3($0.11)($0.12)ViewListenView Earnings Details
8/6/2013Q2 2013($0.14)($0.28)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.13)($0.14)ViewN/AView Earnings Details
3/25/2013Q412$1.09$0.50$135.60 million$123.57 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.16)($0.12)ViewN/AView Earnings Details
11/28/20121.16$1.16$137.19 millionViewN/AView Earnings Details
11/7/2012Q312($0.15)($0.15)ViewN/AView Earnings Details
8/9/2012($0.15)($0.15)ViewN/AView Earnings Details
5/7/2012($0.17)$0.21ViewN/AView Earnings Details
3/6/2012($0.15)($0.27)ViewN/AView Earnings Details
11/8/2011($0.16)$0.22ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cascadian Therapeutics (NASDAQ:CASC) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-1.03 EPS

Dividends

Dividend History for Cascadian Therapeutics (NASDAQ:CASC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cascadian Therapeutics (NASDAQ CASC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 80.35%
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics (NASDAQ CASC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Scott Dunseth MyersInsiderBuy5,500$3.74$20,570.00View SEC Filing  
5/12/2017Scott Dunseth MyersInsiderBuy2,800$4.00$11,200.00View SEC Filing  
3/31/2017Scott Dunseth MyersInsiderBuy2,000$4.11$8,220.00View SEC Filing  
3/28/2017Gwen A FyfeDirectorBuy1,666$4.12$6,863.92View SEC Filing  
3/20/2017Scott Dunseth MyersInsiderBuy1,000$3.93$3,930.00View SEC Filing  
2/2/2017Ted W. LoveDirectorBuy23,000$4.24$97,520.00View SEC Filing  
1/30/2017Christopher S HenneyDirectorBuy25,324$4.11$104,081.64View SEC Filing  
1/27/2017Scott Dunseth MyersInsiderBuy20,500$3.76$77,080.00View SEC Filing  
8/17/2016Scott Dunseth MyersInsiderBuy45,000$1.15$51,750.00View SEC Filing  
6/28/2016Scott Dunseth MyersCEOBuy62,500$0.80$50,000.00View SEC Filing  
6/1/2015Diana HausmanInsiderBuy5,747$4.65$26,723.55View SEC Filing  
3/26/2015Daniel K SpiegelmanDirectorBuy10,000$1.59$15,900.00View SEC Filing  
3/25/2015Daniel K SpiegelmanDirectorBuy10,000$1.63$16,300.00View SEC Filing  
12/17/2014Bvf Partners L P/IlMajor ShareholderBuy378,444$1.82$688,768.08View SEC Filing  
12/15/2014Bvf Partners L P/IlMajor ShareholderBuy224,949$1.88$422,904.12View SEC Filing  
9/23/2014Jay VenkatesanEVPBuy250,000$2.00$500,000.00View SEC Filing  
7/10/2014Daniel K SpiegelmanDirectorSell3,403$1.72$5,853.16View SEC Filing  
2/20/2014Daniel K SpiegelmanDirectorSell12,780$1.96$25,048.80View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy129,000$1.78$229,620.00View SEC Filing  
8/8/2013Bvf Partners P/Ilmajor shareholderBuy258,361$1.65$426,295.65View SEC Filing  
8/1/2013Bvf Partners L P/IlMajor ShareholderBuy338,087$1.74$588,271.38View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy214,467$1.81$388,185.27View SEC Filing  
12/27/2012Wendy W WarrenMajor ShareholderSell57,943$64.30$3,725,734.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cascadian Therapeutics (NASDAQ CASC) News Headlines

Source:
DateHeadline
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index ... - GlobeNewswire (press release)Cascadian Therapeutics Added to the Nasdaq Biotechnology Index ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:44 PM
Cascadian Therapeutics subleases big chunk of CTI BioPharmas waterfront HQCascadian Therapeutics subleases big chunk of CTI BioPharma's waterfront HQ
www.bizjournals.com - December 7 at 5:37 PM
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
finance.yahoo.com - December 7 at 5:37 PM
 Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share Brokerages Anticipate Cascadian Therapeutics, Inc. (CASC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - December 7 at 11:32 AM
Cascadian, Potential Catalysts, Recent Highlights, Tucatinib UpdateCascadian, Potential Catalysts, Recent Highlights, Tucatinib Update
finance.yahoo.com - November 28 at 8:22 AM
Cascadian Therapeutics, Inc. (CASC) Receives Consensus Rating of "Hold" from AnalystsCascadian Therapeutics, Inc. (CASC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 3:46 AM
Array BioPharma To Present At The 2017 Piper Jaffray Healthcare ConferenceArray BioPharma To Present At The 2017 Piper Jaffray Healthcare Conference
www.prnewswire.com - November 22 at 5:44 PM
Cascadian Therapeutics: Upside In Other Her2+ Indications - Seeking AlphaCascadian Therapeutics: Upside In Other Her2+ Indications - Seeking Alpha
seekingalpha.com - November 21 at 5:09 PM
-$0.29 Earnings Per Share Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter-$0.29 Earnings Per Share Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter
www.americanbankingnews.com - November 19 at 3:26 PM
Cascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment ResearchCascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 14 at 5:58 PM
Cascadian Therapeutics, Inc. (CASC) Upgraded to Buy by Zacks Investment ResearchCascadian Therapeutics, Inc. (CASC) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - November 13 at 6:30 PM
Cascadian Therapeutics, Inc. (CASC) Releases Quarterly  Earnings Results, Beats Estimates By $0.01 EPSCascadian Therapeutics, Inc. (CASC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 9 at 5:44 PM
Edited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:01 AM
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Cascadian Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 7:53 PM
Cascadian Therapeutics Inc. to Host Earnings CallCascadian Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 7:52 PM
Cascadian Therapeutics Reports Third Quarter 2017 Financial ResultsCascadian Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 7:52 PM
Cascadian Therapeutics reports 3Q lossCascadian Therapeutics reports 3Q loss
finance.yahoo.com - November 8 at 7:52 PM
Cascadian Therapeutics, Inc. (CASC) Receives Average Rating of "Hold" from BrokeragesCascadian Therapeutics, Inc. (CASC) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 3:50 AM
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - November 1 at 5:44 PM
-$0.29 EPS Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter-$0.29 EPS Expected for Cascadian Therapeutics, Inc. (CASC) This Quarter
www.americanbankingnews.com - October 30 at 3:20 AM
Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in NovemberCascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
finance.yahoo.com - October 24 at 7:12 PM
Financial Analysis: Cascadian Therapeutics (CASC) & The CompetitionFinancial Analysis: Cascadian Therapeutics (CASC) & The Competition
www.americanbankingnews.com - October 15 at 4:08 PM
Cascadian Therapeutics, Inc. (CASC) Downgraded by Zacks Investment Research to "Sell"Cascadian Therapeutics, Inc. (CASC) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - October 11 at 6:32 PM
Cascadian Therapeutics (CASC) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowCascadian Therapeutics (CASC) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 5:02 PM
Cascadian Therapeutics (CASC) Vault on Orphan StatusCascadian Therapeutics (CASC) Vault on Orphan Status
www.baystreet.ca - September 27 at 10:40 PM
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ ... - NasdaqCascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ ... - Nasdaq
www.nasdaq.com - September 27 at 5:38 PM
Cascadian Therapeutics (CASC) versus Its Rivals Critical ContrastCascadian Therapeutics (CASC) versus Its Rivals Critical Contrast
www.americanbankingnews.com - September 26 at 8:12 AM
Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceCascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 5:43 PM
Cascadian Therapeutics, Inc. (CASC) Given Consensus Recommendation of "Hold" by AnalystsCascadian Therapeutics, Inc. (CASC) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 2:50 AM
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress - GlobeNewswire (press release)Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress - GlobeNewswire (press release)
globenewswire.com - September 11 at 10:32 PM
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 CongressTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
finance.yahoo.com - September 11 at 5:32 PM
Cascadian Therapeutics (CASC) "Hold" Rating Reiterated at Cantor FitzgeraldCascadian Therapeutics' (CASC) "Hold" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 11 at 1:22 PM
Cascadian Therapeutics, Inc. (CASC) Now Covered by Analysts at Barclays PLCCascadian Therapeutics, Inc. (CASC) Now Covered by Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:52 PM
2 Names Barclays Is Now Bearish On In Biotech2 Names Barclays Is Now Bearish On In Biotech
finance.yahoo.com - September 7 at 9:42 PM
Cascadian Therapeutics (CASC) "Hold" Rating Reaffirmed at Cantor FitzgeraldCascadian Therapeutics' (CASC) "Hold" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - August 31 at 9:50 AM
Cascadian Therapeutics (CASC) Announces Poster Presentations on Tucatinib in Multiple Tumor Types at ESMOCascadian Therapeutics (CASC) Announces Poster Presentations on Tucatinib in Multiple Tumor Types at ESMO
www.streetinsider.com - August 29 at 2:55 AM
Cascadian Therapeutics Announces Poster Presentations on ... - GlobeNewswire (press release)Cascadian Therapeutics Announces Poster Presentations on ... - GlobeNewswire (press release)
globenewswire.com - August 28 at 9:53 PM
Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 CongressCascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
finance.yahoo.com - August 28 at 4:52 PM
Cascadian Therapeutics, Inc. (NASDAQ:CASC) Insider Acquires $20,570.00 in StockCascadian Therapeutics, Inc. (NASDAQ:CASC) Insider Acquires $20,570.00 in Stock
www.americanbankingnews.com - August 15 at 12:16 AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC) Issues Quarterly  Earnings Results, Beats Expectations By $0.06 EPSCascadian Therapeutics, Inc. (NASDAQ:CASC) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - August 10 at 4:04 PM
Edited Transcript of CASC earnings conference call or presentation 8-Aug-17 8:30pm GMTEdited Transcript of CASC earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:10 PM
Cascadian Therapeutics reports 2Q lossCascadian Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 5:10 PM
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Cascadian Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 4:38 PM
Cascadian Therapeutics Reports Second Quarter 2017 Financial ResultsCascadian Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 4:38 PM
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release)Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - August 1 at 10:46 PM
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 5:44 PM
Cascadian Therapeutics, Inc. (CASC) Short Interest Down 30.2% in JulyCascadian Therapeutics, Inc. (CASC) Short Interest Down 30.2% in July
www.americanbankingnews.com - July 29 at 7:15 AM
Cascadian Therapeutics, Inc. (CASC) Expected to Post Earnings of -$0.25 Per ShareCascadian Therapeutics, Inc. (CASC) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 29 at 12:21 AM
Cascadian Therapeutics, Inc. (NASDAQ:CASC) Receives Consensus Rating of "Buy" from BrokeragesCascadian Therapeutics, Inc. (NASDAQ:CASC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 10:40 AM
Short Interest in Cascadian Therapeutics, Inc. (CASC) Grows By 206.8%Short Interest in Cascadian Therapeutics, Inc. (CASC) Grows By 206.8%
www.americanbankingnews.com - July 14 at 7:34 AM

SEC Filings

Cascadian Therapeutics (NASDAQ:CASC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cascadian Therapeutics (NASDAQ:CASC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cascadian Therapeutics (NASDAQ CASC) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.